CD28-B7 interaction is the co-stimulatory contact between CD28 on a T cell and B7 molecules on an antigen-presenting cell. In Immunobiology, it provides the second signal needed for full T cell activation and helps shape tolerance.
CD28-B7 interaction is the second-signal step that lets a T cell fully turn on after it recognizes antigen in Immunobiology. CD28 is a receptor on the T cell, and B7 molecules, mainly CD80 and CD86, are on activated antigen-presenting cells such as dendritic cells, macrophages, and B cells.
The timing matters. A T cell first gets signal 1 when its T cell receptor binds peptide presented on MHC. That contact tells the cell what antigen it is seeing, but by itself it is not enough for a strong response. If CD28 also binds B7, the T cell receives signal 2, which tells it that the antigen is being presented in a real inflammatory context, not just as background self material.
That extra signal pushes the cell into activation. It boosts IL-2 production, supports clonal expansion, and helps the T cell survive instead of slipping into death or long-term nonresponse. You can think of it as the immune system checking two boxes before spending energy on a full adaptive response.
This is why CD28-B7 is tied to tolerance as well as activation. If a self-reactive T cell sees antigen without enough co-stimulation, it is more likely to become anergic, be deleted, or stay under control rather than attacking tissue. Activated APCs are the ones that raise B7 expression, so the system links T cell activation to danger signals from infection or tissue damage.
The pathway is also balanced by inhibitory signals. CTLA-4 can bind the same B7 molecules and compete with CD28, but it sends a braking signal instead of an activating one. That push-pull between CD28 and CTLA-4 helps keep immune responses strong enough to fight pathogens but restrained enough to avoid autoimmunity.
CD28-B7 interaction sits at the center of central and peripheral tolerance because it helps decide whether a T cell response goes forward or gets shut down. If you are tracing why a self-reactive T cell becomes anergic instead of activated, this is one of the main checkpoints to look for.
It also explains a lot of immune behavior you see across the course. Activated APCs display B7, resting APCs usually do not, and that difference helps show why not every antigen triggers the same response. The pathway connects cell communication, cytokine production, survival, and immune regulation in one step.
This term also sets up comparisons with inhibitory receptors like CTLA-4 and with other tolerance mechanisms such as clonal deletion, activation-induced cell death, and antigen sequestration. Once you know what CD28-B7 does, it becomes much easier to read immune diagrams, follow signaling sequences, and explain why a response was started, strengthened, or blocked.
Keep studying IMMUNOBIOLOGY Unit 11
Visual cheatsheet
view galleryT Cell Activation
CD28-B7 is part of the activation sequence, not a separate side topic. Signal 1 from the T cell receptor identifies the antigen, then CD28-B7 supplies the co-stimulatory push that allows IL-2 production and clonal expansion. Without that second signal, the same antigen encounter can lead to weak activation or tolerance instead of a full response.
Antigen-Presenting Cells (APCs)
APCs are the cells that display B7 molecules during a real immune challenge. Dendritic cells are the classic example, but macrophages and B cells can also provide co-stimulation when they are activated. If you are reading an immune pathway diagram, the APC is the cell that translates danger into the extra signal a T cell needs.
Anergy
Anergy is one likely outcome when a T cell gets signal 1 without enough co-stimulation. Instead of proliferating, the cell becomes functionally unresponsive. CD28-B7 helps prevent that outcome during infections, but the lack of this interaction is useful in tolerance because it stops self-reactive T cells from launching an attack.
ctla-4
CTLA-4 binds the same B7 molecules as CD28, but it sends an inhibitory signal. That means these two receptors compete for the same APC surface proteins while producing opposite effects. A lot of immunobiology questions turn on recognizing that CD28 turns activation up, while CTLA-4 turns it down.
A quiz item or short-answer question might show a T cell interacting with an APC and ask you to name the missing second signal, predict the outcome if B7 is absent, or explain why a self-antigen can fail to activate a T cell. You may also need to read a pathway diagram and identify CD28 as the stimulatory receptor and CTLA-4 as the inhibitory competitor.
In essay prompts or discussion questions on tolerance, use CD28-B7 to explain the difference between antigen recognition and full activation. In case-based questions, look for clues like activated APCs, cytokine production, or T cell proliferation, then connect those details back to co-stimulation. If the prompt describes a T cell that saw antigen but did not respond, CD28-B7 is one of the first mechanisms to check.
These are easy to mix up because both bind B7 on APCs. The difference is the effect: CD28 delivers a stimulatory co-signal that helps activate T cells, while CTLA-4 is inhibitory and dampens the response. When a question asks which molecule promotes activation, CD28 is the one to pick.
CD28-B7 interaction is the co-stimulatory signal that helps a T cell fully activate after antigen recognition.
The T cell receptor gives signal 1, but CD28 binding B7 on an activated APC provides signal 2.
This interaction boosts IL-2 production, T cell survival, and clonal expansion.
If signal 1 happens without enough CD28-B7 co-stimulation, the T cell can become anergic or stay under control.
CTLA-4 competes for B7 and acts as a brake, which is why this pathway matters in tolerance.
It is the co-stimulatory binding between CD28 on a T cell and B7 molecules, CD80 and CD86, on an antigen-presenting cell. In Immunobiology, this interaction supplies the second signal needed for full T cell activation. Without it, antigen recognition alone usually is not enough to trigger a strong response.
The T cell may fail to fully activate even if it recognizes antigen. Depending on the context, that can lead to anergy, deletion, or a weak response instead of clonal expansion. This is one reason the immune system can avoid attacking harmless self antigens.
Both receptors bind B7, so they are often confused. CD28 gives a positive co-stimulatory signal that supports activation, while CTLA-4 sends an inhibitory signal that reduces T cell activity. They act like opposite controls on the same APC surface molecules.
T cells that encounter self antigen without the right co-stimulation are less likely to become active. That helps prevent autoimmunity by keeping self-reactive cells in check. The pathway works alongside other tolerance mechanisms like clonal deletion and anergy.